Thau Ho
GlaxoSmithKline (United States)(US)
Publications by Year
Research Areas
Peptidase Inhibition and Analysis, Epigenetics and DNA Methylation, Ubiquitin and proteasome pathways, Cancer-related Molecular Pathways, Protease and Inhibitor Mechanisms
Most-Cited Works
- → A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models(2015)536 cited
- → A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC(2015)503 cited
- → Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia(2021)262 cited
- → 4-Aryl-1,2,3-triazole: A Novel Template for a Reversible Methionine Aminopeptidase 2 Inhibitor, Optimized To Inhibit Angiogenesis in Vivo(2005)188 cited
- → Structure of human neutrophil collagenase reveals large S1′ specificity pocket(1994)162 cited
- → Discovery and Characterization of a Cell-Permeable, Small-Molecule c-Abl Kinase Activator that Binds to the Myristoyl Binding Site(2011)114 cited
- → Steady-State Kinetic Characterization of Substrates and Metal-Ion Specificities of the Full-Length and N-Terminally Truncated Recombinant Human Methionine Aminopeptidases (Type 2)(2001)69 cited
- → C-terminal region of USP7/HAUSP is critical for deubiquitination activity and contains a second mdm2/p53 binding site(2010)68 cited
- → A Second p53 Binding Site in the Central Domain of Mdm2 Is Essential for p53 Ubiquitination(2006)67 cited
- → Crystal structure of the kinase domain of serum and glucocorticoid‐regulated kinase 1 in complex with AMP–PNP(2007)52 cited